Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
32.59
-0.39 (-1.18%)
At close: Nov 20, 2026, 4:00 PM EST
32.43
-0.16 (-0.49%)
After-hours: Nov 20, 2026, 7:30 PM EST
HRMY Revenue
Harmony Biosciences Holdings had revenue of $268.92M in the quarter ending September 30, 2026, with 12.30% growth. This brings the company's total for the last twelve months to $989.36M, up 19.79% year-over-year. In the year 2025, Harmony Biosciences Holdings had annual revenue of $868.45M with 21.51% growth. That makes Harmony Biosciences Holdings the 7,693rd largest company in the world by revenue and 1,807th in the United States.
Revenue (ttm)
$989.36M
Revenue Growth
+19.79%
P/S Ratio
1.93
Revenue / Employee
$3,376,655
Employees
293
Market Cap
1.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 868.45M | 153.72M | 21.51% |
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | 6.00M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 321.74M |
| Zymeworks | 265.97M |
| Maravai LifeSciences Holdings | 213.00M |
| Septerna | 96.27M |
| Lycia Therapeutics | 4.44M |
| Immunome | 4.02M |
HRMY News
- 3 days ago - Harmony Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Harmony Biosciences Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 18 days ago - Harmony Biosciences Holdings Slides: Q3 2026 - Filings
- 18 days ago - Harmony Biosciences Holdings Earnings release: Q3 2026 - Filings
- 18 days ago - Harmony Biosciences Holdings Quarterly report: Q3 2026 - Filings
- 18 days ago - Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.03B - TheFly
- 18 days ago - Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile - GlobeNewsWire
- 24 days ago - Harmony Biosciences price target lowered to $49 from $51 at Mizuho - TheFly